MCID: EXT027
MIFTS: 37

Extrahepatic Bile Duct Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Extrahepatic Bile Duct Adenocarcinoma

MalaCards integrated aliases for Extrahepatic Bile Duct Adenocarcinoma:

Name: Extrahepatic Bile Duct Adenocarcinoma 12 15
Adenocarcinoma of the Extrahepatic Bile Duct 12 74
Adenocarcinoma of Extrahepatic Bile Duct 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3495
NCIt 51 C7975
UMLS 74 C0279659

Summaries for Extrahepatic Bile Duct Adenocarcinoma

Disease Ontology : 12 An extrahepatic bile duct carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Extrahepatic Bile Duct Adenocarcinoma, also known as adenocarcinoma of the extrahepatic bile duct, is related to papillary extrahepatic bile duct adenocarcinoma and adenocarcinoma, and has symptoms including vomiting, abdominal pain and pruritus. An important gene associated with Extrahepatic Bile Duct Adenocarcinoma is SYP (Synaptophysin), and among its related pathways/superpathways are Neuroscience and Cell adhesion molecules (CAMs). The drugs Gemcitabine and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and pineal.

Related Diseases for Extrahepatic Bile Duct Adenocarcinoma

Diseases related to Extrahepatic Bile Duct Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 148)
# Related Disease Score Top Affiliating Genes
1 papillary extrahepatic bile duct adenocarcinoma 12.5
2 adenocarcinoma 10.4
3 bile duct adenocarcinoma 10.4
4 ependymoma 10.4 ENO2 SYP
5 carotid body cancer 10.3 ENO2 SYP
6 malignant sertoli cell tumor 10.3 ENO2 SYP
7 urinary bladder small cell neuroendocrine carcinoma 10.3 ENO2 SYP
8 auditory system cancer 10.3 ENO2 SYP
9 sinonasal undifferentiated carcinoma 10.3 ENO2 SYP
10 pancreatic somatostatinoma 10.3 ENO2 SYP
11 small cell carcinoma of the bladder 10.3 ENO2 SYP
12 papillary tumor of the pineal region 10.3 ENO2 SYP
13 sensory organ benign neoplasm 10.3 ENO2 SYP
14 middle ear adenoma 10.3 ENO2 SYP
15 pulmonary large cell neuroendocrine carcinoma 10.3 ENO2 SYP
16 atypical follicular adenoma 10.3 ENO2 SYP
17 central nervous system primitive neuroectodermal neoplasm 10.3 ENO2 SYP
18 cerebellum cancer 10.3 ENO2 SYP
19 clear cell ependymoma 10.3 ENO2 SYP
20 cerebral neuroblastoma 10.3 ENO2 SYP
21 cauda equina neoplasm 10.3 ENO2 SYP
22 extraosseous chondrosarcoma 10.3 ENO2 SYP
23 subependymal glioma 10.3 ENO2 SYP
24 malignant teratoma 10.3 ENO2 SYP
25 teratoma 10.3 ENO2 SYP
26 astroblastoma 10.3 ENO2 SYP
27 cerebral ventricle cancer 10.3 ENO2 SYP
28 olfactory nerve neoplasm 10.3 ENO2 SYP
29 pineal gland cancer 10.3 ENO2 SYP
30 autonomic nervous system benign neoplasm 10.3 ENO2 SYP
31 melanotic neuroectodermal tumor 10.3 ENO2 SYP
32 benign ependymoma 10.3 ENO2 SYP
33 nodular ganglioneuroblastoma 10.3 ENO2 SYP
34 ganglioneuroblastoma 10.3 ENO2 SYP
35 pineocytoma 10.3 ENO2 SYP
36 rhabdoid cancer 10.3 ENO2 SYP
37 desmoplastic small round cell tumor 10.3 ENO2 SYP
38 carcinoid tumors, intestinal 10.3 ENO2 SYP
39 cystadenoma 10.3 MME SYP
40 respiratory system benign neoplasm 10.3 ENO2 SYP
41 mucinous ovarian cystadenoma 10.3 ENO2 SYP
42 bone benign neoplasm 10.3 ENO2 SYP
43 esophageal neuroendocrine tumor 10.3 NCAM1 SYP
44 meningeal melanomatosis 10.3 ENO2 SYP
45 ovarian large-cell neuroendocrine carcinoma 10.3 NCAM1 SYP
46 papillary ependymoma 10.3 ENO2 SYP
47 extraskeletal ewing sarcoma 10.3 ENO2 SYP
48 connective tissue benign neoplasm 10.3 ENO2 SYP
49 glomus tumor 10.3 ENO2 SYP
50 hypoganglionosis 10.3 NCAM1 SYP

Graphical network of the top 20 diseases related to Extrahepatic Bile Duct Adenocarcinoma:



Diseases related to Extrahepatic Bile Duct Adenocarcinoma

Symptoms & Phenotypes for Extrahepatic Bile Duct Adenocarcinoma

UMLS symptoms related to Extrahepatic Bile Duct Adenocarcinoma:


vomiting, abdominal pain, pruritus, nausea, icterus, malaise

Drugs & Therapeutics for Extrahepatic Bile Duct Adenocarcinoma

Drugs for Extrahepatic Bile Duct Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
2
Oxaliplatin Approved, Investigational Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
3
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
4 Immunologic Factors Phase 3,Phase 2,Phase 1
5 Antimetabolites Phase 3,Phase 2,Phase 1
6 Anti-Infective Agents Phase 3,Phase 2,Phase 1
7 Antiviral Agents Phase 3,Phase 2,Phase 1
8 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
9 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
10 Liver Extracts Phase 3,Phase 2,Phase 1
11
leucovorin Approved Phase 2 58-05-9 143 6006
12
Fluorouracil Approved Phase 2 51-21-8 3385
13
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
14
Pancrelipase Approved, Investigational Phase 2,Phase 1 53608-75-6
15
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
16
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
17
Melphalan Approved Phase 2 148-82-3 460612 4053
18
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
19
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
20
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
21 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
22 Protective Agents Phase 2
23 pancreatin Phase 2,Phase 1
24 Calcium, Dietary Phase 2
25 Antidotes Phase 2
26 Protein Kinase Inhibitors Phase 2,Phase 1
27
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
28 Antineoplastic Agents, Immunological Phase 2,Phase 1
29 Alkylating Agents Phase 2
30 Antineoplastic Agents, Alkylating Phase 2
31 Cola Phase 2,Phase 1
32 Adjuvants, Immunologic Phase 2
33 Vaccines Phase 2
34 Freund's Adjuvant Phase 2
35
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
36
Durvalumab Approved, Investigational Phase 1 1428935-60-7
37 Guadecitabine Investigational Phase 1 929901-49-5
38 Immunoglobulins Phase 1
39 Antibodies, Monoclonal Phase 1
40 Antibodies Phase 1

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
2 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
3 Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct Unknown status NCT00010088 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
4 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
5 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
6 S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
7 Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
8 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
9 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
10 Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Terminated NCT00085410 Phase 2 bortezomib
11 Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Terminated NCT00012246 Phase 2
12 Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer Completed NCT00544193 Phase 1 gemcitabine hydrochloride
13 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
14 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
15 Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer Completed NCT00266097 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin;gemcitabine hydrochloride;Oxaliplatin
16 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
17 BCX-1777 in Treating Patients With Refractory Cancer Completed NCT00073944 Phase 1 forodesine hydrochloride
18 Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting NCT03257761 Phase 1 Guadecitabine

Search NIH Clinical Center for Extrahepatic Bile Duct Adenocarcinoma

Genetic Tests for Extrahepatic Bile Duct Adenocarcinoma

Anatomical Context for Extrahepatic Bile Duct Adenocarcinoma

MalaCards organs/tissues related to Extrahepatic Bile Duct Adenocarcinoma:

42
Liver, Lung, Pineal, Breast, Ovary, Pancreas, Testis

Publications for Extrahepatic Bile Duct Adenocarcinoma

Articles related to Extrahepatic Bile Duct Adenocarcinoma:

# Title Authors Year
1
Hepatoid Adenocarcinoma of the Extrahepatic Bile Duct in a Patient with Polysplenia Syndrome. ( 28202861 )
2017
2
Differentiation grade for extrahepatic bile duct adenocarcinoma: Assessed by diffusion-weighted imaging at 3.0-T MR. ( 27776649 )
2016
3
Synchronous double primary squamous cell carcinoma and adenocarcinoma of the extrahepatic bile duct: a case report. ( 25986701 )
2015
4
Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. ( 20224368 )
2010
5
Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: case report and review of the literature. ( 20003448 )
2009
6
Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. ( 18754070 )
2008
7
Papillary adenocarcinoma of the extrahepatic bile duct in a Holstein cow. ( 15657275 )
2005
8
Sclerosing adenocarcinoma of the extrahepatic bile duct in a cat. ( 9133721 )
1997
9
Adenocarcinoma of the extrahepatic bile duct in a cat. ( 979176 )
1976

Variations for Extrahepatic Bile Duct Adenocarcinoma

Expression for Extrahepatic Bile Duct Adenocarcinoma

Search GEO for disease gene expression data for Extrahepatic Bile Duct Adenocarcinoma.

Pathways for Extrahepatic Bile Duct Adenocarcinoma

Pathways related to Extrahepatic Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.14 ENO2 NCAM1 SYP
2 11.6 CDH1 NCAM1 SDC1
3 11.42 CDH1 NCAM1 SDC1
4 11.2 MME NCAM1 SDC1
5 11.13 MME SDC1
6 11.04 CDH1 NCAM1
7 10.97 CDH1 SDC1
8 10.67 CDH1 MME NCAM1

GO Terms for Extrahepatic Bile Duct Adenocarcinoma

Cellular components related to Extrahepatic Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection terminus GO:0044306 8.62 MME SYP

Sources for Extrahepatic Bile Duct Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....